ACHV: Achieve Life Sciences, Inc.
About
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
Current Value
$4.301 Year Return
Current Value
$4.301 Year Return
Key Details
Market Cap
$148.91M
P/E Ratio
-3.84
1Y Stock Return
-16.09%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
4.7
Strategies that include ACHV
Stock's related to ACHV
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ORCL | 34.09% | $533.24B | +65.55% | 0.83% |
| GPRO | 31.91% | $184.94M | -66.20% | 0.00% |
| PGEN | 30.43% | $259.78M | -20.80% | 0.00% |
| VYGR | 28.05% | $296.62M | -21.08% | 0.00% |
| SMHI | 27.43% | $189.65M | -42.01% | 0.00% |
| SUNS | 26.64% | $103.02M | +31.64% | 1.41% |
| HRI | 26.55% | $6.19B | +74.88% | 1.20% |
| TG | 26.53% | $244.65M | +48.33% | 0.00% |
| KFRC | 26.36% | $1.12B | -7.67% | 0.64% |
| MLI | 26.36% | $10.43B | +124.64% | 0.86% |
| ARVN | 26.27% | $1.73B | +17.28% | 0.00% |
| AVNT | 26.21% | $4.68B | +49.53% | 2.01% |
| PSTX | 26.16% | $264.13M | +3.83% | 0.00% |
| PLRX | 25.85% | $781.97M | -7.75% | 0.00% |
| HIMS | 25.83% | $5.28B | +198.52% | 0.00% |
| IOSP | 25.83% | $2.95B | +11.70% | 1.31% |
| GNL | 25.75% | $1.68B | -16.51% | 16.15% |
| CRSP | 25.75% | $3.95B | -34.33% | 0.00% |
| RGLD | 25.73% | $9.74B | +27.50% | 1.08% |
| SSL | 25.44% | $1.72B | +22.36% | 1.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| AVAL | -0.02% | $798.90M | -2.75% | 7.20% |
| CPB | -0.05% | $13.23B | +8.54% | 3.29% |
| FENG | 0.08% | $13.53M | +94.49% | 0.00% |
| ERIE | 0.08% | $19.79B | +47.09% | 1.19% |
| SBLK | 0.08% | $2.22B | -4.69% | 11.32% |
| LMT | 0.09% | $128.48B | +20.34% | 2.32% |
| ASR | 0.09% | $7.37B | +19.94% | 0.00% |
| LPLA | -0.10% | $24.20B | +42.81% | 0.37% |
| LLY | 0.10% | $711.91B | +26.02% | 0.68% |
| EFC | 0.12% | $1.12B | -4.98% | 13.17% |
| CHKP | 0.13% | $20.02B | +26.88% | 0.00% |
| CWST | 0.14% | $7.05B | +39.97% | 0.00% |
| ALK | -0.16% | $6.64B | +41.62% | 0.00% |
| WMT | 0.17% | $710.50B | +71.44% | 1.34% |
| ANIP | -0.19% | $1.17B | +8.03% | 0.00% |
| EL | -0.19% | $23.99B | -45.49% | 3.95% |
| FHI | -0.20% | $3.41B | +36.12% | 2.90% |
| TME | -0.21% | $8.06B | +36.01% | 1.21% |
| GHG | -0.22% | $178.30M | -34.88% | 0.00% |
| EXEL | -0.22% | $9.95B | +62.00% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CAVA | -14.15% | $16.55B | +333.79% | 0.00% |
| LIN | -14.14% | $216.69B | +10.56% | 1.20% |
| MOH | -13.49% | $16.94B | -18.86% | 0.00% |
| CRESY | -11.33% | $670.30M | +30.96% | 6.96% |
| QD | -11.32% | $333.18M | +42.94% | 0.00% |
| DXYZ | -11.05% | - | - | 0.00% |
| EDN | -11.02% | $793.99M | +152.89% | 0.00% |
| VIRT | -10.68% | $3.25B | +113.85% | 2.55% |
| WCN | -9.38% | $48.78B | +41.79% | 0.62% |
| CNC | -9.00% | $30.47B | -18.68% | 0.00% |
| MMC | -8.79% | $110.22B | +12.11% | 1.35% |
| AJG | -8.64% | $66.36B | +20.50% | 0.77% |
| CNA | -8.56% | $13.33B | +23.85% | 3.57% |
| UNM | -8.54% | $13.77B | +76.53% | 2.07% |
| GFL | -8.11% | $18.01B | +56.26% | 0.12% |
| YY | -7.96% | $1.47B | -12.25% | 0.00% |
| HLN | -7.81% | $43.23B | +14.51% | 1.63% |
| RNR | -7.72% | $13.75B | +22.34% | 0.58% |
| VERX | -7.67% | $8.33B | +97.20% | 0.00% |
| HNST | -7.29% | $772.35M | +306.91% | 0.00% |
ETF's related to ACHV
News
Yahoo
SEATTLE and VANCOUVER, British Columbia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, today announced that Rick Stewart, CEO of Achieve Life Sciences, and management will be participating at two upcoming investor conferences. Meetings will be conducted at the Jefferies London Healthcare Conference on November 19-
Yahoo
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT 3Q:24 Operational and Financial Results Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported third quarter 2024 results in a November 7th press release distributed after the market's close. The company subsequently held a conference call discussing progress with the ORCA OL trial, pre-commercialization activities and the
SeekingAlpha
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ETCompany ParticipantsNicole Jones - IRRichard Stewart -...
Yahoo
Achieve Life Sciences Inc (ACHV) secures FDA breakthrough designation and completes key trial enrollment, while navigating financial and operational hurdles.
Yahoo
Company to host conference call at 4:30 PM EST today, Thursday, November 7, 2024SEATTLE and VANCOUVER, British Columbia, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, today announced its financial results for the third quarter of 2024 and provided an update on its cytisinicline development program. Recent Highligh
Yahoo
SEATTLE and VANCOUVER, British Columbia, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, today announced it will report its third quarter 2024 financial results and provide a corporate update on the cytisinicline development program on Thursday, November 7, 2024, at 4:30 PM EST. To access the webcast, please use the
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.